Evidence map›Paper›PMID 33995387›Full record

ReviewFrontiers in immunology2021

The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology.

Christina Lamers, Carla Johanna Plüss, Daniel Ricklin

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Article
  2. Current issues in molecular biology · 2026
    Article
  3. Loss of Fgr41 inInfection and immunity · 2026
    Article
  4. Neutrophil CEACAMs and the Inflammatory Response toJournal of innate immunity · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Mechanoregulation of lymphocyte cytotoxicity.Nature reviews. Immunology · 2025
    Review
  9. Article
  10. Article
  11. Effects ofBiomedicines · 2025
    Article
  12. Article
  13. The Complement System.Advances in experimental medicine and biology · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. αStructure (London, England : 1993) · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christina LamersMolecular Pharmacy Unit, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Carla Johanna PlüssMolecular Pharmacy Unit, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Daniel RicklinMolecular Pharmacy Unit, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The β

Indexed as

AnimalsCell MovementDrug DevelopmentHumansIntegrinsLeukocytesLigandsMiceNeutrophilsReceptors, ComplementIntegrinsLigandsReceptors, Complementautoimmune diseasescomplementCR3 (CD11b/CD18)host defenseinflammationintegrin

Identifiers

PMID33995387
PMCPMC8118671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.